ArticleProbiotics and antimicrobial proteins2026
Breast-Milk Lactobacillus Gasseri FN136 Alleviates DSS-Induced Ulcerative Colitis Through Microbiota-Independent Metabolite-Host Interactions.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic, relapsing colonic inflammation defines ulcerative colitis (UC) and heightens long-term colorectal cancer risk. Probiotics, proven beneficial, have emerged as a promising adjunctive strategy for UC management. We conducted a two-tiered evaluation of the breast-milk-derived strain Lactobacillus gasseri FN136. In vitro, FN136 secreted anti-inflammatory amino acids and indole derivatives, displayed pronounced acid- and bile-salt tolerance, and exhibited significant antimicrobial activity. In vivo, daily oral administration of 1 × 10⁹ CFU FN136 markedly attenuated DSS-induced UC: serum L-arginine was restored, splenic regulatory T cells frequency increased by 42.09% (P < 0.05), and nitric oxide production was elevated, while disease activity index, body-weight loss, and colonic shortening were all significantly reduced (P < 0.05). Histopathology revealed intact crypt architecture and diminished inflammatory infiltration; systemic inflammation was suppressed as evidenced by decreased interleukin-6, myeloperoxidase, lipopolysaccharide, and FITC-dextran levels (P < 0.05). However, 16 S rRNA sequencing revealed no significant alterations in global microbial composition, indicating that FN136 exerts protection via a microbiota-independent postbiotic-host axis. Collectively, FN136 mitigates DSS-induced UC by restoring serum arginine and orchestrating immune-barrier homeostasis through a postbiotic pathway, offering a novel framework for precision UC intervention.
Indexed as
Identifiers
41313539What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.